View Financial HealthPing An Biomedical 배당 및 자사주 매입배당 기준 점검 0/6Ping An Biomedical 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공지 • Mar 10Ping An Biomedical Co., Ltd., Annual General Meeting, Mar 18, 2026Ping An Biomedical Co., Ltd., Annual General Meeting, Mar 18, 2026, at 09:00 China Standard Time. Location: 7/f, china united plaza, 1002-1008, tai nan west street, cheung sha wan, kowloon Hong KongReported Earnings • Feb 01Full year 2025 earnings released: CN¥0.69 loss per share (vs CN¥0.071 loss in FY 2024)Full year 2025 results: CN¥0.69 loss per share (further deteriorated from CN¥0.071 loss in FY 2024). Revenue: CN¥34.1m (down 61% from FY 2024). Net loss: CN¥12.8m (loss widened CN¥11.5m from FY 2024).공지 • Jan 10Ping An Biomedical Co., Ltd. announced a financing transactionPing An Biomedical Co., Ltd. entered into a Securities Purchase Agreement and announced a private placement January 9, 2026. The transaction involves participation from individual investors Yao Jinbo, Chairman and CEO of 58 Group Inc.; Wang Donghui, Founder and Managing Partner of Amiba Capital Co., Ltd; and Li Daxue, Chairman and CEO of Magcloud Group Co., Ltd and former Senior Vice President of JD.com and its Lifetime Honorary Advisor.New Risk • Jan 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 25% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Negative equity (-CN¥12m). Earnings have declined by 67% per year over the past 5 years. Minor Risks Market cap is less than US$100m (US$12.7m market cap).New Risk • Nov 26New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.56m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CN¥12m). Earnings have declined by 67% per year over the past 5 years. Market cap is less than US$10m (US$9.56m market cap). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change).Board Change • Nov 02High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Independent Director Jifeng Gao is the most experienced director on the board, commencing their role in 2025. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 05First half 2025 earnings released: CN¥0.23 loss per share (vs CN¥0.013 profit in 1H 2024)First half 2025 results: CN¥0.23 loss per share (down from CN¥0.013 profit in 1H 2024). Revenue: CN¥18.2m (down 60% from 1H 2024). Net loss: CN¥4.23m (down CN¥4.47m from profit in 1H 2024).Buy Or Sell Opportunity • Oct 01Now 23% undervaluedThe stock has been flat over the last 90 days, currently trading at US$0.98. The fair value is estimated to be US$1.28, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 14% over the last 3 years. Meanwhile, the company became loss making.Buy Or Sell Opportunity • Sep 05Now 21% undervaluedThe stock has been flat over the last 90 days, currently trading at US$1.08. The fair value is estimated to be US$1.37, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.6% over the last 3 years. Meanwhile, the company became loss making.Board Change • Aug 12High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Co-Founder & Chairperson of the Board Judy Li is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Buy Or Sell Opportunity • Aug 06Now 27% overvaluedThe stock has been flat over the last 90 days, currently trading at US$1.75. The fair value is estimated to be US$1.38, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 5.6% over the last 3 years. Meanwhile, the company became loss making.공지 • Jul 18Majestic Ideal Holdings Limited has completed an IPO in the amount of $15 million.Majestic Ideal Holdings Limited has completed an IPO in the amount of $15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,500,000 Price\Range: $6 Discount Per Security: $0.42Board Change • Jul 18Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Co-Founder & Chairperson of the Board Judy Li was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 PASW 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: PASW 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Ping An Biomedical 배당 수익률 vs 시장PASW의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (PASW)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Retail Distributors)3.8%분석가 예측 (PASW) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 PASW 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 PASW 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 PASW 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: PASW 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/11 11:31종가2026/05/11 00:00수익2025/09/30연간 수익2025/09/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Ping An Biomedical Co., Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공지 • Mar 10Ping An Biomedical Co., Ltd., Annual General Meeting, Mar 18, 2026Ping An Biomedical Co., Ltd., Annual General Meeting, Mar 18, 2026, at 09:00 China Standard Time. Location: 7/f, china united plaza, 1002-1008, tai nan west street, cheung sha wan, kowloon Hong Kong
Reported Earnings • Feb 01Full year 2025 earnings released: CN¥0.69 loss per share (vs CN¥0.071 loss in FY 2024)Full year 2025 results: CN¥0.69 loss per share (further deteriorated from CN¥0.071 loss in FY 2024). Revenue: CN¥34.1m (down 61% from FY 2024). Net loss: CN¥12.8m (loss widened CN¥11.5m from FY 2024).
공지 • Jan 10Ping An Biomedical Co., Ltd. announced a financing transactionPing An Biomedical Co., Ltd. entered into a Securities Purchase Agreement and announced a private placement January 9, 2026. The transaction involves participation from individual investors Yao Jinbo, Chairman and CEO of 58 Group Inc.; Wang Donghui, Founder and Managing Partner of Amiba Capital Co., Ltd; and Li Daxue, Chairman and CEO of Magcloud Group Co., Ltd and former Senior Vice President of JD.com and its Lifetime Honorary Advisor.
New Risk • Jan 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 25% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Negative equity (-CN¥12m). Earnings have declined by 67% per year over the past 5 years. Minor Risks Market cap is less than US$100m (US$12.7m market cap).
New Risk • Nov 26New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.56m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CN¥12m). Earnings have declined by 67% per year over the past 5 years. Market cap is less than US$10m (US$9.56m market cap). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change).
Board Change • Nov 02High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Independent Director Jifeng Gao is the most experienced director on the board, commencing their role in 2025. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 05First half 2025 earnings released: CN¥0.23 loss per share (vs CN¥0.013 profit in 1H 2024)First half 2025 results: CN¥0.23 loss per share (down from CN¥0.013 profit in 1H 2024). Revenue: CN¥18.2m (down 60% from 1H 2024). Net loss: CN¥4.23m (down CN¥4.47m from profit in 1H 2024).
Buy Or Sell Opportunity • Oct 01Now 23% undervaluedThe stock has been flat over the last 90 days, currently trading at US$0.98. The fair value is estimated to be US$1.28, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 14% over the last 3 years. Meanwhile, the company became loss making.
Buy Or Sell Opportunity • Sep 05Now 21% undervaluedThe stock has been flat over the last 90 days, currently trading at US$1.08. The fair value is estimated to be US$1.37, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.6% over the last 3 years. Meanwhile, the company became loss making.
Board Change • Aug 12High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Co-Founder & Chairperson of the Board Judy Li is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Buy Or Sell Opportunity • Aug 06Now 27% overvaluedThe stock has been flat over the last 90 days, currently trading at US$1.75. The fair value is estimated to be US$1.38, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 5.6% over the last 3 years. Meanwhile, the company became loss making.
공지 • Jul 18Majestic Ideal Holdings Limited has completed an IPO in the amount of $15 million.Majestic Ideal Holdings Limited has completed an IPO in the amount of $15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,500,000 Price\Range: $6 Discount Per Security: $0.42
Board Change • Jul 18Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Co-Founder & Chairperson of the Board Judy Li was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.